CD274 and colorectal carcinoma: Nevertheless, other studies revealed a small subset of MSS CRC patients who may still benefit from anti-PD-1/PD-L1 antibodies.45 Therefore, the identification of predictive biomarkers for MSS CRC patients is essential to improve patient outcome.